Latest Entries »

In Silico Genesis presented our Alzheimer’s strategy to the One Nucleus CNS Leadership Seminar Series held in London, on the 11th of Feb. 2013.

isg_on2

This seminar will look at:

• The Prime Minister’s Dementia Challenge
• Pharmacotherapy for Alzheimer’s disease – progress and prospects
• The emerging scientific advances that may enable greater success in the future

Agenda:

10.30 – Registration

11.00 – Welcome from the Chair
Janet Knowles, Partner, Eversheds

11.10 – The Prime Minister’s Dementia Challenge
Mark Treherne, CEO, Life Sciences Investment Organisation, UKTI

11.30 – What are the prospects of slowing the progression of Alzheimer’s disease?
Prof Alan Palmer, Director MS Therapeutics

12.00 – What insights do biomarkers provide into the recent Phase III failures?
Andrea Les, Senior Imaging Scientist, IXICO

12.20 – Q&A with the speakers

12.45 – Networking Lunch

13.45 – Introduction from the Chair
Philip Oliver

13.45 Is there a future for the amyloid theory in treating Alzheimer’s disease?
Eric Karran, Alzheimer’s Research UK

14.05 Targeting Tau hyperphosporylation in AD
Ian Pike, COO, Proteome Sciences

14.25 – Genetic basis of Alzheimer disease susceptibility
Prof. Julie Williams, Cardiff University School of Medicine

14.45 – FGL Peptides as neuroprotectives in AD
Steve Rees, COO, ENKAM Pharmaceuticals A/S

15.05 – Translational genomic medicine and companion diagnostic development
Kimberley Treherne
(then, Williams), In Silico Genesis

15.25 – Closing Remarks from one Nucleus
Tony Jones, Director of Business Development, One Nucleus

15.30 – Networking drinks

16.30 – Close

Shown above can be found at http://onenucleus.com/onenucleus-events?id=692.

In Silico Genesis signed up a Confidential Disclosure Agreement with ISIS Innovation, the commercial arm of the University of Oxford, and the University of Oxford and plus Baroness Professor Susan Greenfield of Pharmacology of the University of Oxford in June 2013. This 4 way CDA was put in place, following an initial collaborative work with Prof. Greenfield’s lab on a repurposed drug for Alzheimer’s Disease.

In Silico Genesis signed up a Confidential Disclosure Agreement with Public Health England (PHE), previously Health Protection Agency, in June 2013. This CDA was reaffirming an initial CDA placed in October, 2011 between Health Protection Agency (HPA) and In Silico Genesis (ISG) about the antiviral work in collaboration. 

Public Health England (PHE) https://www.gov.uk/government/organisations/public-health-england

In Silico Genesis signed up NDA contract (Confidentiality Agreement) with University of Bristol, following initial discussions with faculty members of Centre for Computational Chemistry, School of Chemistry, University of Bristol, England in May/June 2013. This NDA contract was communicated via Research Enterprise Development, on behalf of the Department of Chemistry, for the official signatory of the University of Bristol. This confidentiality agreement bears a specific scope of the permitted purpose, which is relating to research on potential drugs for new medicinal targets for influenza treatments.

We met at e-Infrastructure South Conference and his presentation was of great interest to the work of In Silico Genesis, in the area of the current drug resistance of the existing flu medicines and how it can be alleviated. In order to achieve this, it is necessary to understand what it is causing the resistance at the structural level. His work was spot on, beautifully so.

What was more impressive still, was how the University of Bristol handled the NDA contract, in a most professional and thorough manner. At the time, I was sceptical of anything that was from outside of my Oxford University. They showed me the grace and understanding, instead of walking away from what could have been very unpleasant to them. For that, I am thankful to the University of Bristol, regardless of what may become of this NDA contract in the years to come.

In Silico Genesis signed up a Confidential Disclosure Agreement with Imanova, a spin-off company from GlaxoSmithKline (GSK), in April 2015. This CDA was originally signed by the CEO of Imanova on the 19th of April 2013, following a mutual interest identified in the area of CNS, whilst both companies attending One Nucleus CNS Leadership Seminar series in London on the 11th of February 2013.

Since then, Imanova and In Silico Genesis have both been selected to represent the strengths of British companies on the UK Trade and Investment CNS Trade Mission to British Embassy Seoul and British Embassy Tokyo, in the first week of November 2014. I was very impressed by the quality of the work presented by Imanova, and more so by his warmth and genuine respect which he showed to the people of South Korea and of Japan at the Embassies.

I had the pleasure of introducing my father to the CEO of Imanova at British Embassy Seoul. Then, I was deeply touched by how he opened his seminar at British Embassy Tokyo, sharing with the audience openly what Japan really meant to him and his daughter. I returned my signed copy of the original CDA bearing his signature, to the CEO of Imanova on the 19th of April, 2015. He is a hard-working CEO and believes in what Imanova can do to help people.

Hello World. Blessings and peace be unto you and all your beloved in abundance this year. May the almighty creator God gives you joy, happiness and exceedingly abundant above goodness over your life and every walk of your path.

In Silico Genesis has had a good start of this new year 2015. We are very thankful to the UK Trade and Investment & One Nucleus, respectively, for approaching In Silico Genesis to follow up on the UKTI CNS Trade Mission, which took place in November 2014 at British Embassy Seoul and British Embassy Tokyo. It is such a pleasure to be asked to report back the good things that the UKTI has done for In Silico Genesis, by both organisations. I am grateful. I give praise and thanks to my almighty God for the exceeding goodness that He brings to In Silico Genesis. Glory to God.

My father took this picture, when he accompanied me to British Embassy Seoul, representing In Silico Genesis together with me.

The British Ambassador to South Korea with me (the curly blonde in the centre) at British Embassy Seoul, on the UKTI CNS Trade Mission.

The British Ambassador to South Korea with me (the curly blonde in the centre) at British Embassy Seoul, on the UKTI CNS Trade Mission.

In Silico Genesis received an invitation by a representative of UKTI Japan, to present the last slot of UKTI CNS Trade Mission’s seminars held in British Embassy Tokyo on Friday, the 7th of November, 2014.

This generosity has been made possible by a fellow British delegate who presented at British Embassy Seoul, alongside with the presentation by In Silico Genesis on Tuesday, the 4th of November, 2014.

Kimberley of In Silico Genesis is deeply thankful to UKTI Japan and the central CNS Trade Mission team in London altogether, making this amazing opportunity possible.

ukti
isg_on2

ISG is hitting Seoul in the first week of November 2014, to represent the CNS work done by this British Company in the foreign soil, for the first time in the company’s history, since early 2011. Come and see us, if you want to see what we are made of in real. I am proud of UK Trade and Investment for making this very unlikely mission possible.

 

ukti

Meet ISG Logo!

ISGaward2014

In Silico Genesis receives 2014 United Kingdom Excellence Award

August 15th 2014 – In Silico Genesis has been selected for the 2014 United Kingdom Excellence Award amongst all its peers and competitors by the US Institute for Advancement of Trade & Commerce (USIATC).

Each year the USIATC conducts business surveys and industry research to identify companies that have achieved demonstrable success in their local business environment and industry category. They are recognized as having enhanced the commitment and contribution of small businesses through service to their customers and community. Small businesses of this caliber enhance the consumer driven stature that United Kingdom is renowned for.

In Silico Genesis has consistently demonstrated a high regard for upholding business ethics and company values. This recognition by USIATC marks a significant achievement as an emerging leader within various competitors and is setting benchmarks that the industry should follow.

As part of the industry research and business surveys, various sources of information were gathered and analyzed to choose the selected companies in each category. This research is part of an exhaustive process that encapsulates a year long immersion in the British business climate.

About USIATC

The USIATC is a leading authority on researching, evaluating and recognizing companies across a wide spectrum of industries that meet its stringent standards of excellence. It has spearheaded the idea of independent enterprise and entrepreneurial growth allowing businesses of all sizes to be recognized locally and encouraged globally.

Particular emphasis is given to meeting and exceeding industry benchmarks for customer service, product quality and ethical practices. Industry leading standards and practices have been developed and implementation of the same has been pioneered by the dedicated efforts of the business community and commerce leadership.

More information on USIATC can be found at http://www.USIATC.org

ISGaward

FOR IMMEDIATE RELEASE:

In Silico Genesis receives 2013 United Kingdom Excellence Award

May 24th 2014 – In Silico Genesis has been selected for the 2013 United Kingdom Excellence Award amongst all its peers and competitors by the US Trade & Commerce Institute (USTCI).

Each year the USTCI conducts business surveys and industry research to identify certain international companies that have achieved demonstrable success in their local business environment and industry category. They are recognized as having enhanced the commitment and contribution of small businesses through service to their customers and community. Companies of this caliber enhance the consumer driven stature that the United Kingdom economy is renowned for.

In Silico Genesis has consistently demonstrated a high regard for upholding business ethics and company values. This recognition by USTCI marks a significant achievement as an emerging leader within various competitors and is setting benchmarks that the industry should follow.

As part of the industry research and business surveys, various sources of information were gathered and analyzed to choose the selected companies in each category. This research is part of an exhaustive process that encapsulates a year long immersion in the business climate of the United Kingdom economy.

About USTCI

The USTCI is a leading authority on researching, evaluating and recognizing companies across a wide spectrum of industries that meet its stringent standards of excellence. It has spearheaded the idea of independent enterprise and entrepreneurial growth allowing businesses of all sizes to be recognized locally and encouraged globally.

Particular emphasis is given to meeting and exceeding industry benchmarks for customer service, product quality and ethical practices. Industry leading standards and practices have been developed and implementation of the same has been pioneered by the dedicated efforts of the business community and commerce leadership.

More information on USTCI can be found at http://www.USTCI.org